Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209794 | 0.98 | AKR1C1 (0.44) | AKR1C1PTPN1GSK3BHPGDLMNA | |
| SCHEMBL28139686 | 0.80 | AKR1C1 (0.42) | AKR1C1HPGDLMNAHDAC4KMT2A | |
| SCHEMBL29155399 | 0.79 | AKR1C1 (0.45) | AKR1C1HPGDLMNAHDAC4KMT2A | |
| SCHEMBL8529984 | 0.79 | AKR1C1 (0.45) | AKR1C1HPGDLMNAHDAC4KMT2A | |
| SCHEMBL3678905 | 0.78 | OPRM1 (0.33) | HDAC4 | |
| SCHEMBL4611297 | 0.78 | GSK3B (0.51) | GSK3BHPGDLMNAKMT2ACES2 | |
| SCHEMBL4117188 | 0.78 | KEAP1 (0.35) | HPGDLMNAKMT2AALDH1A1 | |
| SCHEMBL64920 | 0.78 | AKR1C1 (0.44) | AKR1C1LMNAHDAC4CES2CES1 | |
| Benzene SCHEMBL29067363 | 0.78 | HDAC4 (0.46) | AKR1C1HPGDLMNAHDAC4KMT2A | |
| SCHEMBL6695613 | 0.78 | HDAC4 (0.46) | AKR1C1HPGDLMNAHDAC4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503343-B | Preparation method of photoinitiator 184 | 常州久日化学有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-2297076-A1 | PROCESS FOR THE PREPARATION OF AROMATIC ALPHA-HYDROXY KETONES | Lamberti SpA (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065962-A1 | PROCESS FOR THE PREPARATION OF AROMATIC ALPHA-HYDROXY KETONES | MENEGUZZO ENZO | 2011-03-17 | — | — | US | disclosed |
| WO-2009135895-A1 | PROCESS FOR THE PREPARATION OF AROMATIC ALPHA-HYDROXY KETONES | LAMBERTI SPA (IT) | 2009-11-12 | — | — | WO | disclosed |
| EP-1280779-B1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORP (FI) | 2005-08-24 | — | — | EP | disclosed |
| EP-1280779-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2003-02-05 | — | — | EP | disclosed |
| US-6362211-B2 | FOR THERAPY OF NEUROLOGICAL, PSYCHIATRIC OR COGNITION DISORDER, DIABETES, LIPOLYTIC DISORDER, ORTHOSTATIC HYPOTENSION, OR SEXUAL DYSFUNCTION | ORION CORPORATION (FI) | 2002-03-26 | — | — | US | disclosed |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ORION CORPORATION (FI) | 2002-01-31 | — | — | US | disclosed |
| WO-2001085698-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2001-11-15 | — | — | WO | disclosed |
| EP-0094347-B1 | PROCESS FOR THE PREPARATION OF 1-HYDROXYKETONES | CIBA-GEIGY AG (CH) | 1985-07-10 | — | — | EP | disclosed |
| EP-0094347-A1 | Process for the preparation of 1-hydroxyketones | CIBA-GEIGY AG (CH) | 1983-11-16 | — | — | EP | disclosed |
| US-4328356-A | Process for preparing esters of arylacetic acids from alpha-halo-alkylarylketones | MONTEDISON S.P.A. (IT) | 1982-05-04 | — | — | US | disclosed |
| US-4012524-A | DIURETICS, SALURETICS, HYPOURICEMICS, HYPOTENSIVES, ANTIEDEMICS | MERCK & CO., INC. (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065962-A1 | PROCESS FOR THE PREPARATION OF AROMATIC ALPHA-HYDROXY KETONES | KHK, BCKDK, PAH | AKR1C1 46/4885PTPN1 4423/4885GSK3B 2042/4885 |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ADRB2, ADRB1, ADRA1A | AKR1C1 594/4885PTPN1 3877/4885GSK3B 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.